Organicell Announces Positive Results Of Initial COVID-19 Zofin™ Patient Trial In India And Trial Expansion
Miami, FL (April 28, 2021) – Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced positive results for the first ten COVID-19 patients treated with Zofin™ in India. This initial trial is being conducted in conjunction with Organicell’s Indian partner, CWI India, with whom Organicell entered into a product testing and distribution agreement on February 9, 2021 to study the effects of Zofin™ on moderate to severe COVID-19 patients. [Read more…]
Breakthrough Paper Outlines Path to Heart Regeneration After Cardiac Injury
A groundbreaking study from Neobiosis, a global expert in regenerative medicine, explains how a never-before-described process may open the door to regenerating damaged hearts. A peer-reviewed research paper from Dr. Ian White published in the journal Stem Cells and Regenerative Medicine explains how his studies of mouse hearts could be used to defeat a disease that kills 650,000 Americans each year.
ALACHUA, FLA., APRIL 21, 2021 – Cardiovascular disease kills more than 650,000 Americans annually.(1) Those who survive myocardial infarction remain at risk of death because the human heart has a very limited ability to repair itself. No one has yet found a method that leads to cardiovascular regeneration for a damaged human heart. But all that may change thanks to a revolutionary medical paper written by Dr. Ian White, President and CSO of Neobiosis, a company that focuses on the science of regenerative medicine.
Organicell Completes Enrollment For Its Expanded Access Trial To Treat COVID-19 Patients With Zofin™
Miami, FL (April 22, 2021) — Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that the company has completed enrollment for its U.S. Food and Drug Administration (FDA) granted expanded access trial for Zofin for the treatment of COVID-19. [Read more…]
Organicell Announces FDA Approval Of IND Application For The Use Of Zofin™ In The Treatment Of Osteoarthritis
Miami, FL (April 21, 2021) — Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for its lead product, Zofin™, in the treatment of knee osteoarthritis. [Read more…]
- « Previous Page
- 1
- …
- 46
- 47
- 48
- 49
- 50
- …
- 97
- Next Page »